Navigation Links
Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
Date:1/5/2009

RICHMOND, Calif., Jan. 5 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 2:00 pm (PT) on Monday, January 12, 2009 at the J.P. Morgan Healthcare Conference in San Francisco.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and amyotrophic lateral sclerosis (ALS). Other therapeutic development programs are focused on HIV/AIDS, cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic areas including Dow AgroSciences, Sigma-Aldrich and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation and completion of stages of ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
2. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
3. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
4. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
5. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
6. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
7. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
8. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
9. Sangamo BioSciences to Present at the Canaccord Adams Global Growth Conference
10. Sangamo BioSciences to Present at the BMO Capital Markets Focus on Healthcare Conference
11. Sangamo BioSciences Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Genedata, a leading provider of ... occasion with a strong presence at Bio-IT World Conference & Expo 2017 in ... invitation to all attendees to view posters on the entire range of ...
(Date:5/23/2017)... ... May 23, 2017 , ... Kathy Goin is joining ... Operations. She brings years of expertise in establishing and leading clinical operations at ... a licensed occupational therapist, through a variety of leadership roles in Clinical Operations, ...
(Date:5/22/2017)... ... May 22, 2017 , ... Baltimore biotech firm, PathSensors, ... Biohealth community in developing and issuing recommendations to grow Maryland's biohealth industry and ... by 2023. , The recommendations are contained in a report ...
(Date:5/19/2017)... ... May 19, 2017 , ... ... Program. Academic researchers with technologies ripe for commercialization, and who are affiliated ... Delaware, are encouraged to submit proposals. QED, now in its tenth round, is ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:3/30/2017)... HONG KONG , March 30, 2017 ... developed a system for three-dimensional (3D) fingerprint identification by adopting ground ... technology into a new realm of speed and accuracy for use ... applications at an affordable cost. ... ...
Breaking Biology News(10 mins):